Should access to GLP-1 weight-loss drugs be publicly reimbursed?
14 votes|10 arguments|0 source
The evidence base remains contested, and headline studies often haven't been independently replicated at scale. @@no_5
Quasi-experimental study exploiting staggered platform rollouts across US universities.
Comparative overview of how surrogacy is regulated across 46 European jurisdictions, from outright bans to fully commercial frameworks.
Why off-patent molecules with oncology signals stall, and what public trial infrastructure could change.